tbuckley/cabot-search huggingface dataset:
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
Authors: Jotin Marango, Manabu Shimoyama, Hitomi Nishio, Julia A. Meyer, Dong-Joon Min, Andres Sirulnik, Yolanda Martinez-Martinez, Marta Chesi, P. Leif Bergsagel, Ming-Ming Zhou, Samuel Waxman, Boris A. Leibovitch, Martin J. Walsh, Jonathan D. Licht
Journal: Blood (2007)
Interleukin-1 receptor antagonist in normal and psoriatic epidermis.
Authors: C Hammerberg, W P Arend, G J Fisher, L S Chan, A E Berger, J S Haskill, J J Voorhees, K D Cooper
Journal: Journal of Clinical Investigation (1992)

The objective of these studies was to characterize the IL-1 inhibitory activity present in normal and psoriatic epidermis from clinically stable lesions. Fractionation of normal epidermal cytosol on a molecular sizing column failed to reveal the presence of IL-1 inhibitory bioactivity. However, specific ELISAs indicated that both the IL-1 receptor antagonist (IL-1ra) and IL-1 alpha were present in overlapping peaks. Further fractionation of the normal epidermal cytosol by anion exchange chromatography separated these two molecules, revealing the IL-1 inhibitory bioactivity of the IL-1ra molecule. Similar studies on psoriatic epidermal cytosol indicated the presence of IL-1 inhibitory bioactivity and IL-1ra protein. The IL-1 inhibitory bioactivity of both normal and psoriatic cytosol was neutralized by a mAb specific for IL-1ra. The ratio of IL-1ra to IL-1 alpha proteins was significantly increased in involved psoriatic skin compared with normal skin. By Western blot analysis this IL-1ra was approximately 20 kD, slightly larger than monocyte-derived IL-1ra and equivalent to an intracellular variant of IL-1ra expressed by keratinocytes. Polymerase chain reaction indicated the presence of mRNA for both forms of IL-1ra in normal epidermis, with both forms increased in psoriatic-involved skin. Immunofluorescence studies revealed the IL-1ra protein to be concentrated in the stratum granulosum of normal skin and in the basal-midbasal layers of psoriatic epidermis. These results suggest that the balance between intracellular IL-1ra and IL-1 alpha may be an important influence on keratinocyte growth and/or differentiation, as well as on the inflammatory potential of IL-1 in injured skin.
IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses.
Authors: Z Xing, J Gauldie, G Cox, H Baumann, M Jordana, X F Lei, M K Achong
Journal: Journal of Clinical Investigation (1998)

IL-6 is induced often together with the proinflammatory cytokines TNFalpha and IL-1 in many alarm conditions, and circulating IL-6 plays an important role in the induction of acute phase reactions. However, whether this endogenous IL-6 plays any additional pro- or antiinflammatory roles in local or systemic responses remains unclear. In this study, the role of IL-6 in acute inflammatory responses was investigated in animal models of endotoxic lung or endotoxemia by using IL-6+/+ and IL-6-/- mice. Aerosol exposure of endotoxin induced increased IL-6 and proinflammatory cytokines TNFalpha and MIP-2 and a neutrophilic response in the lung of IL-6+/+ mice. However, the levels of TNFalpha and MIP-2 and neutrophilia were significantly higher in the lung of IL-6-/- mice. The rate of neutrophil apoptosis in these mice was similar to that in IL-6+/+ mice. A low constitutive level of antiinflammatory cytokine IL-10 was not enhanced by endotoxin and remained similar in the lung in both IL-6+/+ and IL-6-/- mice. Systemically, intraperitoneal delivery of endotoxin resulted in much more pronounced circulating levels of TNFalpha, MIP-2, GM-CSF, and IFNgamma in IL-6-/- mice than in IL-6+/+ mice, and administration of recombinant IL-6 to IL-6-/- mice abolished these differences. In contrast, circulating IL-10 levels were induced to a similar degree in both IL-6+/+ and IL-6-/- mice. Thus, our studies reveal that endogenous IL-6 plays a crucial antiinflammatory role in both local and systemic acute inflammatory responses by controlling the level of proinflammatory, but not antiinflammatory, cytokines, and that these antiinflammatory activities by IL-6 cannot be compensated for by IL-10 or other IL-6 family members.
1131 THE MYOSTATIN SYSTEM IS EXPRESSED IN THE LIVER AND ITS ACTIVATION MEDIATES PROFIBROGENIC ACTIONS IN HEPATIC STELLATE CELLS (HSC) VIA c-Jun N-TERMINAL KINASE (JNK)
Authors: A. Caligiuri, W. Delogu, A. Provenzano, S. Galastri, M. Pinzani, F. Marra
Journal: Journal of Hepatology (2013)
Amiodarone-Associated Thyroid Dysfunction
Authors: Sara A. Thorne, Isobel Barnes, Paul Cullinan, Jane Somerville
Journal: Circulation (1999)

Amiodarone is widely used in adults with congenital heart disease, but no systematic study has been published on its effects on thyroid function in these patients. A retrospective study was performed to examine the frequency of amiodarone-associated thyroid dysfunction in adults with congenital heart disease and to identify any contributing factors.All adults (16 to 60 years old) with congenital heart disease were identified from a database if they had no preexisting thyroid disease, had taken amiodarone for >/=6 months, and were currently followed up by 1 consultant (J.S.). Ninety-two patients were found and evaluated for thyroid status and cardiac complications. A case-control analysis was performed, with patients matched for duration of amiodarone therapy. Of the 92 patients (age, 34.9+/-10.2 years; range, 18 to 60 years), 36% developed thyroid dysfunction: 19 became hyperthyroid and 14 hypothyroid. Female sex and complex cyanotic heart disease were significant risk factors for developing thyroid dysfunction (odds ratios, 3.0 and 7.00; P=0.04 and 0.01, respectively). Previous Fontan-type surgery also appeared to be a risk factor for developing thyrotoxicosis (odds ratio, 4.0; P=0.17), and amiodarone >200 mg/d a risk factor for thyroid dysfunction (odds ratio, 4.0; P=0.60).Amiodarone-associated thyroid dysfunction is common in adults with congenital heart disease. Women and those with complex cyanotic lesions are at particular risk, as patients may be who have had Fontan-type surgery or are taking >200 mg/d of amiodarone. Amiodarone should be used only when other antiarrhythmics are ineffective or contraindicated. Vigilance is required to detect and treat thyroid dysfunction.
Rectal Polyps and Cancer
Authors: Michael B. Shimkin
Journal: JAMA (1963)

<h3>To the Editor:</h3> —Recently accumulating data that cast serious doubt on the association of adenomatous polyps and the development of rectal carcinoma should not be misinterpreted as negating the importance of sigmoidoscopy. It would be useful to have some characteristic to identify the cancer-prone patients who require more careful observations. Adenomatous polyps apparently do not fulfill this role. Thus, patients<i>without</i>polyps should have the same periodic re-examinations that previously were suggested for polyp-bearers, until better indices of increased cancer risk are defined. There does not appear to be any substantive difference of opinion between Dr. Roberts' comment and the editorial.
Outcome Results of the 1996-1999 Patterns of Care Survey of the National Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus
Authors: Mohan Suntharalingam, Jennifer Moughan, Lawrence R. Coia, Mark J. Krasna, Lisa Kachnic, Daniel G. Haller, Christopher G. Willet, Madhu J. John, Bruce D. Minsky, Jean B. Owen
Journal: Journal of Clinical Oncology (2005)

Purpose A Patterns of Care Study of patients treated from 1996 to 1999 evaluated the national practice for patients receiving radiation therapy for carcinoma of the esophagus in the United States. Methods A national survey was conducted at 59 institutions in a stratified random sample selected from a master list of radiation therapy facilities throughout the United States. Patient, tumor, and treatment characteristics were evaluated. Multivariate comparisons of survival times were made using the Cox proportional hazards model. Results Adenocarcinoma was diagnosed in 51% of patients and squamous cell carcinoma in 49% of patients. Sixteen percent of patients were clinical stage (CS) I (using the 1983 American Joint Committee on Cancer system), 39% were CS II, and 33% were CS III. Significant variables in the multivariate analysis of survival times included clinical stage, treatment approach, and facility size. Patients with CS III disease had a higher hazard risk of death as compared with CS I patients (hazard ratio [HR], 2.01; P = .001), whereas those treated with chemoradiotherapy followed by surgery (HR, 0.32; P &lt; .0001) had a decreased risk of death compared with chemoradiotherapy-only patients. Patients at small centers had a higher risk of death (HR, 1.32; P = .03) compared with patients treated at larger facilities. Conclusion Concurrent chemoradiotherapy continued to be the most commonly utilized treatment approach during the time period studied. The observation that patients undergoing surgical resection following chemoradiation have a decreased HR or chance of death compared with other treatment schemes supports the need for a randomized trial comparing these strategies.
Case of cholestatic hepatitis with celecoxib did not fulfil international criteria
Authors: F. M Arellano
Journal: BMJ (2002)

EDITOR—O'Beirne and Cairns reported a case of cholestatic hepatitis in association with celecoxib.1 This case does not, however, fulfil the accepted international criteria for cholestatic hepatitis as it was not confirmed histologically.2 Biochemical criteria of cholestatic hepatitis require the presence of alkaline phosphatase activity over twice the upper normal limit or a ratio of alkaline phosphatase to alanine aminotransferase activity >2, or both.2 Neither was fulfilled, even when using aspartate aminotransferase as a surrogate of alanine aminotransferase, which was not provided. Moreover, the patient did …
374 MELATONIN IMPROVES MITOCHONDRIAL RESPIRATORY CHAIN ACTIVITY (MRC) AND LIVER HISTOLOGY IN OB/OB MICE
Authors: P. Solís-Muñnoz, I. García-Ruiz, E. Gómez-Izquierdo, T. Muñnoz-Yagüe, J.A. Solís-Herruzo
Journal: Journal of Hepatology (2010)
LEFT BUNDLE BRANCH BLOCK INFLUENCES CORONARY FLOW RESERVE IN NON-ISCHEMIC DILATED CARDIOMYOPATHY
Authors: Quirino Ciampi, Lauro Cortigiani, Lorenza Pratali, Fausto Rigo, Chiara Manicardi, Bruno Villari, Eugenio Picano, Rosa Sicari
Journal: Journal of the American College of Cardiology (2014)
Contractile Versus Microvascular Reserve for the Determination of the Extent of Myocardial Salvage After Reperfusion
Authors: Jiri Sklenar, Gustavo Camarano, N. Craig Goodman, Suad Ismail, Ananda R. Jayaweera, Sanjiv Kaul
Journal: Circulation (1996)

Background We hypothesized that microvascular reserve is a better indicator of the extent of viable myocardium postinfarction than contractile reserve, especially in the presence of a residual stenosis of the infarct-related artery. Methods and Results Fifteen dogs with various infarct sizes were studied after reperfusion. Contractile reserve, studied by use of dobutamine echocardiography, and microvascular reserve, studied by use of myocardial contrast echocardiography, were measured both before and after creation of a stenosis. In the absence of a stenosis, the relation between infarct size, expressed as percent of risk area, and wall thickening improved with increasing doses of dobutamine ( r =.41, .71, and .90 for 5, 10, and 15 μg·kg − 1 ·min − 1 , respectively; P &lt;.01 for dobutamine 15 μg·kg − 1 ·min − 1 ). In the presence of a stenosis, however, the relation was poor for all doses of dobutamine ( r =.22, .57, and .32 for 5, 10, and 15 μg·kg − 1 ·min − 1 , respectively; P &lt;.01 for 15 μg·kg − 1 ·min − 1 dobutamine in the absence of a stenosis). There was a fair correlation between infarct size and perfusion defect size on myocardial contrast echocardiography after reperfusion ( r =.82), with the defect size underestimating infarct size by approximately 20%. This relationship improved ( P &lt;.01) during infusions of both adenosine ( r =.99) and dobutamine ( r =.94) in the absence of a stenosis. The correlations between infarct size and perfusion defect on myocardial contrast echocardiography also remained good in the presence of a stenosis ( r =.95 and .81 for adenosine and dobutamine, respectively; P =NS compared with stenosis). Conclusions Microvascular reserve is superior to contractile reserve for definition of the spatial topography of necrosis and hence the extent of viable myocardium within the infarct bed after reperfusion, particularly when a residual stenosis is present in the infarct-related artery.
Diagnosis of Herpes Simplex Virus in Patients With Erythema Multiforme—Reply
Authors: Barry Ladizinski, Kachiu C. Lee
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Behavioral and Physiological Characteristics in Hyperuricemia
Authors: Richard R. Lanese
Journal: JAMA (1969)

A total of 210 white male state employees, aged 40 to 59, participated in a screening program for risk factors for coronary heart disease, and 19.5% were hyperuricemic, defined as a serum uric acid level of 7.0 mg/100 cc or above (enzymatic spectrophotometric method). These hyperuricemic subjects were compared with nonhyperuricemic subjects on the behavioral variables of age, education, conflict, internal versus external control, perception of change with respect to early and present life situations, job stability, cigarette smoking, and physical activity. The physiological variables considered were blood pressure, serum creatinine values, serum cholesterol levels, and ponderal index. Hyperuricemia was associated with increased perception of change, decreased job stability, greater cigarette smoking, elevated blood pressure, and lower ponderal index. These associations suggest the possibility that changing living patterns, particularly in persons of upward mobility, may be an important contributing factor in hyperuricemia.
DETERMINANTS OF LEFT VENTRICULAR VORTEX RING CIRCULATION IN REMODELED HEARTS: IMPROVED VISUALIZATION OF CARDIAC FLUID-STRUCTURE INTERACTIONS BY ECHO CONTRAST PARTICLE IMAGING VELOCIMETRY
Authors: Haruhiko Abe, Giuseppe Caracciolo, Arash Kheradvar, Jagat Narula, Partho P. Sengupta
Journal: Journal of the American College of Cardiology (2011)
Superior survival using living donors and donor-recipient matching using a novel living donor risk index
Authors: David S. Goldberg, Benjamin French, Peter L. Abt, Kim Olthoff, Abraham Shaked
Journal: Hepatology (2014)

The deceased-donor organ supply in the U.S. has not been able to keep pace with the increasing demand for liver transplantation. We examined national Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) data from 2002-2012 to assess whether living donor liver transplantation (LDLT) has surpassed deceased donor liver transplantation (DDLT) as a superior method of transplantation, and used donor and recipient characteristics to develop a risk score to optimize donor and recipient selection for LDLT. From 2002-2012, there were 2,103 LDLTs and 46,674 DDLTs that met the inclusion criteria. The unadjusted 3-year graft survival for DDLTs was 75.5% (95% confidence interval [CI]: 75.1-76.0%) compared with 78.9% (95% CI: 76.9-80.8%; P &lt; 0.001) for LDLTs that were performed at experienced centers (&gt;15 LDLTs), with substantial improvement in LDLT graft survival over time. In multivariate models, LDLT recipients transplanted at experienced centers with either autoimmune hepatitis or cholestatic liver disease had significantly lower risks of graft failure (hazard ratio [HR]: 0.56, 95% CI: 0.37-0.84 and HR: 0.76, 95% CI: 0.63-0.92, respectively). An LDLT risk score that included both donor and recipient variables facilitated stratification of LDLT recipients into high, intermediate, and low-risk groups, with predicted 3-year graft survival ranging from &gt;87% in the lowest risk group to &lt;74% in the highest risk group. Conclusion : Current posttransplant outcomes for LDLT are equivalent, if not superior, to DDLT when performed at experienced centers. An LDLT risk score can be used to optimize LDLT outcomes and provides objective selection criteria for donor selection in LDLT. (Hepatology 2014;60:1717–1726)
Cardiac Progenitor Cells and Biotinylated Insulin-Like Growth Factor-1 Nanofibers Improve Endogenous and Exogenous Myocardial Regeneration After Infarction
Authors: M. Elena Padin-Iruegas, Yu Misao, Michael E. Davis, Vincent F.M. Segers, Grazia Esposito, Tomotake Tokunou, Konrad Urbanek, Toru Hosoda, Marcello Rota, Piero Anversa, Annarosa Leri, Richard T. Lee, Jan Kajstura
Journal: Circulation (2009)

Background— Cardiac progenitor cells (CPCs) possess the insulin-like growth factor-1 (IGF-1)-IGF-1 receptor system, and IGF-1 can be tethered to self-assembling peptide nanofibers (NF-IGF-1), leading to prolonged release of this growth factor to the myocardium. Therefore, we tested whether local injection of clonogenic CPCs and NF-IGF-1 potentiates the activation and differentiation of delivered and resident CPCs enhancing cardiac repair after infarction. Methods and Results— Myocardial infarction was induced in rats, and untreated infarcts and infarcts treated with CPCs or NF-IGF-1 only and CPCs and NF-IGF-1 together were analyzed. With respect to infarcts exposed to CPCs or NF-IGF-1 alone, combination therapy resulted in a greater increase in the ratio of left ventricular mass to chamber volume and a better preservation of +dP/dt, −dP/dt, ejection fraction, and diastolic wall stress. Myocardial regeneration was detected in all treated infarcts, but the number of newly formed myocytes with combination therapy was 32% and 230% higher than with CPCs and NF-IGF-1, respectively. Corresponding differences in the volume of regenerated myocytes were 48% and 115%. Similarly, the length density of newly formed coronary arterioles with both CPCs and NF-IGF-1 was 73% and 83% greater than with CPCs and NF-IGF-1 alone, respectively. Importantly, activation of resident CPCs by paracrine effects contributed to cardiomyogenesis and vasculogenesis. Collectively, CPCs and NF-IGF-1 therapy reduced infarct size more than CPCs and NF-IGF-1 alone. Conclusions— The addition of nanofiber-mediated IGF-1 delivery to CPC therapy improved in part the recovery of myocardial structure and function after infarction.
Definition of Acute Respiratory Distress Syndrome
Authors: Silvio A. Namendys-Silva, Marisol Hernández-Garay
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized Trial of Telephone Outreach to Improve Medication Adherence and Metabolic Control in Adults With Diabetes
Authors: Patrick J. O’Connor, Julie A. Schmittdiel, Ram D. Pathak, Ronald I. Harris, Katherine M. Newton, Kris A. Ohnsorg, Michele Heisler, Andrew T. Sterrett, Stanley Xu, Wendy T. Dyer, Marsha A. Raebel, Abraham Thomas, Emily B. Schroeder, Jay R. Desai, John F. Steiner
Journal: Diabetes Care (2014)

Medication nonadherence is a major obstacle to better control of glucose, blood pressure (BP), and LDL cholesterol in adults with diabetes. Inexpensive effective strategies to increase medication adherence are needed.In a pragmatic randomized trial, we randomly assigned 2,378 adults with diabetes mellitus who had recently been prescribed a new class of medication for treating elevated levels of glycated hemoglobin (A1C) ≥8% (64 mmol/mol), BP ≥140/90 mmHg, or LDL cholesterol ≥100 mg/dL, to receive 1) one scripted telephone call from a diabetes educator or clinical pharmacist to identify and address nonadherence to the new medication or 2) usual care. Hierarchical linear and logistic regression models were used to assess the impact on 1) the first medication fill within 60 days of the prescription; 2) two or more medication fills within 180 days of the prescription; and 3) clinically significant improvement in levels of A1C, BP, or LDL cholesterol.Of the 2,378 subjects, 89.3% in the intervention group and 87.4% in the usual-care group had sufficient data to analyze study outcomes. In intent-to-treat analyses, intervention was not associated with significant improvement in primary adherence, medication persistence, or intermediate outcomes of care. Results were similar across subgroups of patients defined by age, sex, race/ethnicity, and study site, and when limiting the analysis to those who completed the intended intervention.This low-intensity intervention did not significantly improve medication adherence or control of glucose, BP, or LDL cholesterol. Wide use of this strategy does not appear to be warranted; alternative approaches to identify and improve medication adherence and persistence are needed.